SOX2OT variant 7 contributes to the synergistic interaction between EGCG and Doxorubicin to kill osteosarcoma via autophagy and stemness inhibition

SOX2OT variant 7 contributes to the synergistic interaction between EGCG and Doxorubicin to kill osteosarcoma via autophagy and stemness inhibition

Abstract Background Doxorubicin is the preferred chemotherapeuticdrug for osteosarcoma treatment of which clinical efficacy is limited because of its chemo-resistance and cardiac toxicity. It is necessary to develop the combination regimen with complementary molecular mechanisms to reduce the side e...

Full description

Bibliographic Details
Main Authors: Wanchun Wang, Ding Chen, Kewei Zhu
Format: Article
Language:English
Published: BMC 2018-02-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Osteosarcoma
Doxorubicin
EGCG
SOX2OT
Autophagy
Cancer stem cells
Online Access:http://link.springer.com/article/10.1186/s13046-018-0689-3

Internet

http://link.springer.com/article/10.1186/s13046-018-0689-3

Similar Items